Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 pivotal trial, according to a press release from Tenpoint Therapeutics.
The BRIO-II trial met prespecified primary endpoints agreed to by the FDA, European Medicines Agency and UK Medicines and Healthcare products Regulatory Agency. Brimochol PF (carbachol/brimonidine tartrate fixed-dose combination) demonstrated improvements in near vision vs. vehicle at all study time points up to 8 hours (P < .008). Additionally, it demonstrated reduction in pupil size at all time